Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 15/20 | 0.82 |
| ▸ | ABL1 | P00519 | 11/20 | 0.82 |
| ▸ | BCR | P11274 | 7/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.82 |
| ▸ | EGFR | P00533 | 1/20 | 0.80 |
| ▸ | PRKCA | P17252 | 1/20 | 0.80 |
| ▸ | KIT | P10721 | 6/20 | 0.75 |
| ▸ | KDR | P35968 | 2/20 | 0.71 |
| ▸ | ABL2 | P42684 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903621 | 0.91 | PDGFRA (0.82) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL9820 | 0.90 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL3055349 | 0.89 | PDGFRA (0.89) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL13498211 | 0.89 | PDGFRA (0.88) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL9782 | 0.89 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL29498750 | 0.89 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL11932096 | 0.88 | PDGFRA (0.86) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL9677 | 0.88 | PDGFRA (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL11927842 | 0.88 | ABL1 (1.00) | PDGFRAABL1BCRPDGFRBEGFR | |
| SCHEMBL25512963 | 0.88 | PDGFRA (0.86) | PDGFRAABL1BCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084039-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4011882-B1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4011882-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | Purdue Research Foundation (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011882-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | Purdue Research Foundation (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20210198208-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198208-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2021-07-01 | — | — | US | disclosed |
| US-11001559-B2 | 4-substituted aminoisoquinoline derivatives | PURDUE RESEARCH FOUNDATION (US) | 2021-05-11 | — | — | US | disclosed |
| US-11001559-B2 | 4-substituted aminoisoquinoline derivatives | PURDUE RESEARCH FOUNDATION (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3496717-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | Purdue Research Foundation (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190177278-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190177278-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2018035072-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018035072-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177278-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | MCL1, ABL1, FLT3 | PDGFRA 1480/4885ABL1 2/4885BCR 15/4885 |
| US-11001559-B2 | 4-substituted aminoisoquinoline derivatives | MCL1, ABL1, FLT3 | PDGFRA 1480/4885ABL1 2/4885BCR 15/4885 |
| US-20210198208-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | MCL1, ABL1, FLT3 | PDGFRA 1480/4885ABL1 2/4885BCR 15/4885 |
| US-20250084039-A1 | 4-SUBSTITUTED AMINOISOQUINOLINE DERIVATIVES | MCL1, ABL1, FLT3 | PDGFRA 1480/4885ABL1 2/4885BCR 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.